OpenAI acquires Orchestra Bio to push drug-discovery agents
What happened
On October 20, OpenAI said it has acquired Orchestra Bio, a drug-discovery coordination platform, and plans to fold its team and technology into Rosalind, OpenAI's life-science research models and tools. Orchestra's agents track study progress, flag activities and timelines hit by problems, and gather information and compare response options for scientists and project leads to decide on. The two aim to build agents that link scientific findings to the research, decisions and next steps needed to move a drug candidate forward. The acquisition is complete; the team and technology integration is still only a stated plan.
Written by AI from the coverage · updated 2 hours ago
Coverage
Follow the reports to see the story from different sides.
- OpenAI NewsOpenAI acquires Orchestra Bio
OpenAI 已收购 Orchestra Bio，计划将其团队和技术与生命科学研究模型及工具 Rosalind 整合。双方旨在构建智能体，将科学发现与推进候选药物所需的研究、决策和后续步骤衔接起来。Orchestra 的智能体可监测研究进度、识别受问题影响的活动与时间安排，并汇集信息、比较应对方案，供科学家和项目负责人决策。
Heat over time
Not enough continuous observations to draw a trend yet.